Patents by Inventor Sean Proll
Sean Proll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120129170Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: ApplicationFiled: January 3, 2012Publication date: May 24, 2012Applicant: CELLTECH R&D INC.Inventors: MARY E. BRUNKOW, SEAN PROLL, BRYAN W. PAEPER, KAREN STAEHLING-HAMPTON
-
Patent number: 8110357Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: GrantFiled: August 27, 2010Date of Patent: February 7, 2012Assignee: Celltech R&D, Inc.Inventors: Mary E Brunkow, Sean Proll, Brian W Paeper, Karen Staehling-Hampton
-
Publication number: 20110070588Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: ApplicationFiled: August 27, 2010Publication date: March 24, 2011Applicant: Celltech R&D Inc.Inventors: Mary E. BRUNKOW, Sean PROLL, Bryan W. PAEPER, Karen STAEHLING-HAMPTON
-
Patent number: 7799523Abstract: Compositions and methods are provided for determining in a subject a risk for having, or presence of, altered bone mineral density such as osteoporosis or osteopenia or other conditions characterized by decreased or increased bone density. Specifically, the invention relates to determination of a sclerostin gene region nucleotide polymorphism (SRP) in DNA of the sclerostin gene region of human chromosome 17. In certain embodiments, SRPs that indicate an increased risk for altered bone mineral density occur as gender-associated polymorphisms. Isolated polynucleotides comprising representative SRPs are also provided.Type: GrantFiled: April 3, 2003Date of Patent: September 21, 2010Assignee: Celltech R & D, Inc.Inventors: Bryan W. Paeper, Sean Proll, Patrick R. Charmley, Mary E. Brunkow, Andreas Gerardus Uitterlinden
-
Publication number: 20100003755Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: ApplicationFiled: July 3, 2007Publication date: January 7, 2010Applicant: UCB SAInventors: Mary E. Brunkow, Sean Proll, Bryan W. Paeper, Karen Staehling-Hampton
-
Publication number: 20060083740Abstract: The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.Type: ApplicationFiled: November 21, 2002Publication date: April 20, 2006Applicant: Celltech R&D, Inc.Inventors: Fred Ramsdell, Sean Proll, Karen Staehling-Hampton, Mark Appleby, Leon Garcia-Martinez
-
Publication number: 20030235847Abstract: Compositions and methods are provided for determining in a subject a risk for having, or presence of, altered bone mineral density such as osteoporosis or osteopenia or other conditions characterized by decreased or increased bone density. Specifically, the invention relates to determination of a sclerostin gene region nucleotide polymorphism (SRP) in DNA of the sclerostin gene region of human chromosome 17. In certain embodiments, SRPs that indicate an increased risk for altered bone mineral density occur as gender-associated polymorphisms. Isolated polynucleotides comprising representative SRPs are also provided.Type: ApplicationFiled: April 3, 2003Publication date: December 25, 2003Applicants: Celltech R&D, Inc., Erasmus University RotterdamInventors: Bryan W. Paeper, Sean Proll, Patrick R. Charmley, Mary E. Brunkow, Andreas Gerardus Uitterlinden
-
Publication number: 20030157543Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: ApplicationFiled: January 27, 2003Publication date: August 21, 2003Applicant: Celltech R&D, Inc.Inventors: Mary E. Brunkow, Sean Proll, Bryan W. Paeper, Karen Staehling-Hampton
-
Patent number: 6475739Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: GrantFiled: July 30, 2001Date of Patent: November 5, 2002Assignee: Celltech R&D, Inc.Inventors: Mary E. Brunkow, Sean Proll, Bryan Paeper, Karen Staehling-Hampton
-
Publication number: 20020076720Abstract: The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.Type: ApplicationFiled: July 30, 2001Publication date: June 20, 2002Inventors: Mary E. Brunkow, Sean Proll, Bryan Paeper, Karen Staehling-Hampton